2020 AABB Annual Meeting On-Demand

Oct 3, 2020 ‐ Oct 3, 2020



Access to the 2020 AABB Annual Meeting On-Demand sessions expires on December 31, 2022. Each session includes the on-demand recording and a downloadable MP3 audio file. Presentation handouts are not available/included.

Planning Committee Disclosures


Sessions

AM20-11: Towards Personalized Hct and HbS Targets in Transfusion for Sickle Cell Disease

Oct 3, 2020 3:45pm ‐ Oct 3, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Despite the advent of new drug options in sickle cell disease, red cell transfusion remains a mainstay of treatment. Its recommended indications- for example, for silent stroke- are in fact increasing. A major issue with transfusion, however, is lack of clinical methodologies and algorithms to provide a “personalized medicine” approach to target Hct and HbS% goals; this lack may contribute, for example, to progressive cerebral infarction or vasculopathy despite transfusion in up to 45% of patients. Transfusion targets may need to be tailored to the end-organ most at risk in a particular patient. In this session, three experts will discuss methodologies with potential to inform personalized transfusion targets for prevention or treatment of end-organ damage. Dr. Fields will explain current MR imaging methodologies to assess vascular hemodynamics in the brain, which can potentially be used to assess stroke risk. Dr. Detterich will describe various potentially real-time peripheral blood measurements to assess transfusion needs and response. Dr. Wood will appraise methods being developed in his lab to quantitate polymerized Hb and its effects in various organ-specific vascular beds.

Learning Objectives:
  • Explain magnetic resonance imaging (MRI) measurements, including cerebral blood flow, oxygen extraction fraction and cerebral metabolic rate of oxygen utilization, that can be used to assess the effect of clinical intervention with transfusion or drugs on the vascular hemodynamics of the brain.
  • Describe the insights that peripheral blood measures of aggregate blood flow and vascular dysfunction, such as hematocrit to viscosity ratio, flow-mediated dilation, and red cell deformability, can reveal about Hct and HbS targets in transfusion.
  • Appraise developing lab methodologies to quantify hemoglobin polymer in individual RBCs and whole blood rheology in physiologically relevant vascular mimics to inform Hct and HbS targets in transfusion.
Speaker(s): Disclosures
  • Jon Detterich, MD : Nothing to disclose
  • Melanie Fields, MD : Stockholder: Preclara Biosciences; Honoraria: Bluebird Bio
  • David Wood, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-12: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation

Oct 3, 2020 3:45pm ‐ Oct 3, 2020 4:45pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity. Mechanistic insights into HSC biology could be leveraged to further improve the strategies available to maintain and expand functional HSCs in vitro. Overcoming these hurdles is critical to effectively use HSCs for off-the-shelf allogeneic HSC transplantation or gene-editing of autologous HSCs for treatments of hematological disease and malignancies. In this session, we will examine the latest molecular mechanisms discovered thus far to harness the capacity of HSCs to maintain blood cell lineage output and durable HSC self-renewal towards development of novel methods to produce unlimited HSCs in vitro for use in transfusion applications.

Learning Objectives:
  • Discuss the theories of hematopoietic stem cell (HSC) cycling and maintenance of stem cell self-renewal in vitro.
  • Define the molecular mechanisms that contribute exhaustion of HSCs in culture conditions.
  • Describe the latest advances in technologies and methods to expand functional HSCs and de novo generation of HSCs in vitro.
Speaker(s): Disclosures
  • Shahin Rafii, MD : Founder and non-paid consultant: Angiocrine Bioscience
  • Guy Sauvageau : Stockholder, Employee: Excellthera
  • Larry Luchsinger : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-13: Multidisciplinary Team Building: Anesthesiology, Nursing and the Transfusion Service

Oct 3, 2020 6:00pm ‐ Oct 3, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

The purpose of this session will be to engage learners in active discussions on the strategies that work to implement change in a multidisciplinary team involving anesthesiologists, operating room nurses, and blood bank specialists, with regards to transfusion practices in the operating room. Basic quality improvement techniques will be reviewed, including process mapping, analysis and redesign, and implementing and communicating key changes and training plans. The speakers will emphasize the importance of understanding how to improve processes. In addition, the concept of the Gemba Walk (getting first-hand experience and knowledge about the work being done by the front lines) will be introduced, which is critical for leaders and team members to appreciate the value created by multidisciplinary teamwork and attempts to improve processes. 

The session will highlight the challenges of making change in a multidisciplinary environment, with emphasis on the perspectives of the anesthesiologist, operating room nurse, and blood bank specialists. With our goal of excellence in patient care with respect to transfusion of blood products, the speakers will explore the unique challenges faced by each role of the multidisciplinary team, including time and productivity pressures, as well as the positive and limiting aspects of the team model (resident, nurse anesthetist, etc.). The role those aspects play in engaging the multidisciplinary team to adhere to best practices in transfusion medicine will be emphasized. The discussion will use recent Quality Improvement Projects at our centers as models for improving communication between departments and among providers and technical staff with the overriding goal of maximizing patient safety.

Learning Objectives:
  • Produce a process map of blood product transport and handling from blood bank to the operating room
  • Evaluate the function of a multidisciplinary team using a Gemba Walk (getting first-hand experience and knowledge about the work being done by the front lines)
  • Determine the ways leaders can improve team building strategies
Speaker(s): Disclosures
  • Judith Forbes, MT, SBB : Nothing to disclose
  • Prakash Patel, MD, FASE : Nothing to disclose
  • Maureen Hemingway, R.N. : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-14: The Spectrum of Pediatric Emergency Transfusion: Before Arrival, in Hospital and Beyond

Oct 3, 2020 6:00pm ‐ Oct 3, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

The full spectrum of pediatric emergency transfusion includes transfusion that occur before arrival to the hospital as well as events that occur at arrival or during hospitalization. In this session, the speakers will address the outcome of pediatric patients experiencing acute blood loss in these various settings. Speakers will describe the demographics and blood usage of pediatric patients that require transfusion during emergency transport to the hospital and after arrival. Best practices in a pediatric massive transfusion protocol for the hospitalized patient will be reviewed with an emphasis on how to optimize the process. The blood product selection for massive transfusion in pediatrics patients will highlight the rationale and current data on the experience with Low Titer Group O Whole Blood in pediatric patients.

Learning Objectives:
  • Explain the demographics, transfusion practices and outcomes of pediatric patients who receive pre-hospital transfusion with RBCs and plasma.
  • Formulate the critical components of a massive transfusion protocol for pediatric patients to include antifibrinolytics and coagulation factor concentrates.
  • Evaluate the evidence describing the use of whole blood to resuscitate pediatric patients requiring emergency transfusion in the prehospital or in hospital phase of resuscitation.
Speaker(s): Disclosures
  • Cyril Jacquot, MD PhD : Nothing to disclose
  • Cassandra Josephson, MD : Consultant: Immucor, Octapharma, Biomet Zimmer; Grant/Research Support: Medtronics, Sysmex
  • Philip Spinella, MD, FCCM : Consultant: Hemantext, Secure Transfusion Services
Standard: $25.00
Members: $20.00

AM20-15: Controversies in Stem Cell Tourism: Practical and Ethical Considerations

Oct 3, 2020 6:00pm ‐ Oct 3, 2020 7:00pm
Expiration Date: Dec 31, 2022

Credits: None available.

Based on a thorough review of social media, newspaper articles and scientific publications, a role for internet in influencing stem cell tourism has emerged. A tally of data from these sources suggests an increase in the number of patients exploring stem cell tourism under the pretext of “Management of Hope”. Potential participants should, however, be informed of the risk factors involved with the usage of unregulated and unproven stem cell therapies. This session will also caution clinicians and researchers in other countries to exercise restraint in using or recommending any unregulated stem cell products.

This session has three main objectives: first to educate attendees on the background, history and current trends in Stem Cell Tourism - the unregulated commercial stem-cell industry, a practice that is not only potentially harmful to individual patients but also undermines attempts to study stem-cell therapies in clinical trials. The Program Chair, Dr. Indira Guleria, will give this introductory lecture. She will discuss the perils of stem cell tourism by discussing her collaborative study (NEJM 2016) where glioproliferative lesions developed in a patient who received stem cell infusions.

Second, attendees will learn about clinical research in neurodegenerative diseases. Diseases such as traumatic brain injury, macular degeneration, cerebral palsy are common targets of stem cell tourism. These diseases have also been linked to serious complications arising because of stem cell tourism. Invited to talk about these diseases is Dr. Sally Temple, Director of the Neural Stem Cell Institute who is an expert on use of cellular therapy in neurodegenerative disease conditions.

Finally, attendees of this session will be introduced to the regulatory, legislative and ethical aspects of Stem cell Tourism. Regulation of stem cell therapy and enforcement of pre-existing legislation varies from country to country and has allowed stem cell tourism to outpace legislation in various countries. We plan to invite Dr. Henry Greely who is a Professor of Law at Stanford University and specializes in ethical, legal, and social issues arising from advances in the biosciences, particularly in human stem cell research to address the regulatory aspect of stem cell tourism.

Learning Objectives:
  • Describe the concept of stem cell tourism and learn about the current trends and the role of social media in spread of this industry
  • Discuss issues and risks involved in using unproven stem cell therapies for various conditions, especially neurologic diseases
  • Recognize the regulatory, legislative and ethical issues associated with unregulated stem cell therapies being used across different countries
Speaker(s): Disclosures
  • Wade Atkins, MS, MT(ASCP)SBB, CQA, ASQ : Nothing to disclose
  • Kapil Bharti, PhD : Nothing to disclose
  • Indira Guleria, Ph.D. Diplomate (ABHI) : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-16: Oral Abstract Session -- Donor/Collection

Oct 3, 2020 7:15pm ‐ Oct 3, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on Donor/Collection

Learning Objectives:
  • Describe model changes in platelet apheresis in the new FDA environment
  • Analyze the convalescent plasma donor population at NYBC
  • Discuss overcoming the challenges of alternative gender classifications
  • Discuss correlating ferritin levels and RBC storage
Speaker(s): Disclosures
  • Nancy Van Buren, MD : Nothing to disclose
  • Travis Berry : <p><br></p>
  • Joanne Tan : <p><br></p>
  • Saagar Jain : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-17: Enlightening Studies in Therapeutic Apheresis: What’s Been Done, What's Happening, and What’s to Come!

Oct 3, 2020 7:15pm ‐ Oct 3, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Therapeutic apheresis is applied to patients with a spectrum of organ and life-threatening diseases in both the inpatient and outpatient settings. While the positive impact of apheresis therapy is recognized, meaningful clinical studies in apheresis medicine are challenging to perform. In this informative and interactive session, three past presidents of the American Society for Apheresis will discuss the trials and tribulations of performing significant investigations in apheresis medicine, as well as review apheresis studies that they believe have been the most meaningful to the field. Consequential studies that are actively underway in therapeutic apheresis that have the potential to alter current practices, as well as those trials which should be conducted, will also be discussed. Therapeutic apheresis interventions to be analyzed include therapeutic plasma exchange, red cell exchange, extracorporeal photopheresis, LDL-apheresis, and therapeutic cytapheresis. An exciting panel discussion involving the audience about needed future investigations, barriers to involvement in clinical trials, and opportunities for collaboration will follow the presentations by these past presidents.

Learning Objectives:
  • Explain the challenges in performing clinical studies in therapeutic apheresis.
  • Recognize the most impactful studies involving therapeutic plasma exchange, red cell exchange, extracorporeal photopheresis, LDL-apheresis, and therapeutic cytapheresis.
  • Identify therapeutic apheresis studies that are currently underway, as well as those needing to be performed, that have the potential to significantly influence the practice of apheresis medicine.
Speaker(s): Disclosures
  • Zbigniew Szczepiorkowski, MD, PhD : Consultant: Grifols, Fresenius Kabi, IHIT, Warsaw; Research/Grant Support: Grifols, Fresenius Kabi
  • Jeffrey Winters, MD : Nothing to disclose
  • Yanyun Wu, MD, PhD : Consultant: Verax, Terumo, Blood Diagnostic LLC; Honoraria: UpToDate
Standard: $25.00
Members: $20.00

AM20-18: Mechanisms of Hematopoietic Stem Cells Towards Rejuvenation of the Aging Hematopoietic System

Oct 3, 2020 7:15pm ‐ Oct 3, 2020 8:15pm
Expiration Date: Dec 31, 2022

Credits: None available.

Presented in collaboration with Be The Match BioTherapies®

A hallmark of the ageing hematopoietic system is a skewing of lineage output from balanced to myeloid-biased, which is hypothesized to result in compromised adaptive immunity and predisposition toward myeloid malignancies in aging individuals. More recently, changes in the composition of a heterogeneous HSC population with age (the population shift model) is being increasingly recognized to account for lineage output changes and the observed hematopoietic ageing phenotype may result from an expansion of myeloid-biased HSCs with exhaustion of lymphoid-biased and balanced HSCs. Importantly, research efforts continue investigate the molecular mechanisms associated with aging HSCs. This session will highlight theories recent discoveries of the ageing HSC compartment and molecular mechanisms underlying these processes which potentially can be targeted to rejuvenate aged HSC functions.

Learning Objectives:
  • Define the current models of hematopoietic stem cell (HSC) heterogeneity and changes that occur with the ageing process.
  • Discuss the molecular mechanisms that contribute to HSC output skewing and senescence that occur with age and approaches to revert the aging-associated hallmarks of aged HSCs.
  • Describe HSC clonal dominance and expansion of HSCs that occurs with age and contribution to malignant transformations.
Speaker(s): Disclosures
  • Ross Levine : Research/Grant Support: Prelude, Roche; Honoraria: Gilead, Janssen, Lilly, Incyte, Estellar, BMS; Board/Advisory Board: Qiagon, Mission Bio, Cy Imago, Isoplexis, Auron, Ajax
  • Jason Butler : Consultant: Angiocrine Bioscience; Stockholder: Angiocrine Bioscience
  • Gerald de Haan, MSc, PhD : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-19: Oral Abstract Session -- New Blood Group Antigens and Novel Alleles

Oct 4, 2020 10:00am ‐ Oct 4, 2020 11:00am
Expiration Date: Dec 31, 2022

Credits: None available.

Oral abstract session on New Blood Group Antigens and Novel Alleles

Learning Objectives:
  • Describe how the c.217T (p.73Cys) change led to the identification of a new allele in the Sc blood group system.
  • Review and describe the molecular alterations which leads to changes in the expression of GPB.S and GPB.s and can relate these issues to other GPB variants such as St(a), SAT and TSEN.
  • List the high frequency alleles now attributed to the Gerbich blood group system that appeared to be anti-Ge2 in a patient that is GE:2 by molecular testing.
  • Discuss the role of KLF1 in the role of regulating antigen expression in several blood groups.
  • Describe the molecular basis of the Lu(a-b-) and three known mechanisms causing the LU null phenotype.
Speaker(s): Disclosures
  • Roser Hoffman : Nothing to disclose
  • Judith Aeschlimann : Nothing to disclose
  • Christine Lomas-Francis, MSc, FIBMS : Nothing to disclose
  • Thierry Peyrard, Pharmd, PhD, EurSpLM : Nothing to disclose
Standard: $25.00
Members: $20.00

AM20-20: Comparing and Contrasting Centrifuge and Membrane Therapeutic Plasma Exchange

Oct 4, 2020 10:00am ‐ Oct 4, 2020 11:00am
Expiration Date: Dec 31, 2022

Credits: None available.

Plasma separation for the purposes of therapeutic plasma exchange (TPE) can be accomplished through the use of a centrifuge or a membrane. Centrifuge TPE is frequently utilized in the United States, particularly among transfusion medicine-based apheresis services. Membrane TPE is also available in the United States and not uncommonly performed among nephrology-based apheresis services on already existing dialysis equipment. In fact, two membranes are FDA approved for membrane TPE in the United States. Regrettably, the literature comparing these two TPE methods is scant, and there is not widespread familiarity with membrane TPE within the greater transfusion medicine community. While an increasing number of nephrologists and nephrology trainees are exposed to membrane TPE, membrane TPE is largely overlooked in most transfusion medicine training, practice, and literature. The goal of this interdisciplinary session is to provide a forum in which transfusion medicine and nephrology practitioners can, in real time, compare these two methods and achieve a greater understanding of the strengths and weaknesses of each method. First, the technical aspects of both centrifuge and membrane TPE will be discussed, including, but not limited to vascular access, anticoagulation, efficiency of plasma removal, properties of the centrifuge or membrane, and replacement fluid. Focus will then be shifted to a review of the literature that attempts to address the important question of whether centrifuge TPE and membrane TPE are clinically equivalent. Opportunities for further research will be discussed, as will strategies by which practitioners of transfusion medicine can become more familiar with membrane TPE and by which practitioners of nephrology can become more familiar with centrifuge TPE.

Learning Objectives:
  • Examine the technical aspects of both membrane and centrifuge therapeutic plasma exchange
  • Discuss the literature exploring the use of membrane therapeutic plasma exchange and the clinical settings in which is commonly performed
  • Compare the strengths and weaknesses of both membrane and centrifuge therapeutic plasma exchange
Speaker(s): Disclosures
  • Julie Katz Karp, MD : Nothing to disclose
  • Casey Gashti : Consultant: NxStage Medical Inc.
  • Amber Sanchez : Nothing to disclose
Standard: $25.00
Members: $20.00
Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content